Welcome to our dedicated page for Alpha Tau Medical news (Ticker: DRTS), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical stock.
Alpha Tau Medical Ltd. develops Alpha DaRT, an intratumoral alpha-radiation therapy being studied for solid tumors. News about DRTS centers on clinical development, regulatory interactions and scientific presentations for Alpha DaRT across oncology programs including recurrent cutaneous squamous cell carcinoma, pancreatic cancer, recurrent glioblastoma, and head and neck cancer.
Company updates frequently cover trial data, feasibility and safety findings, patient enrollment milestones, FDA device-pathway activity, conference abstracts and global study expansion. The news also reflects the company's focus on localized alpha-emitter radiation intended to treat tumors while limiting exposure to surrounding tissue.
Alpha Tau (Nasdaq: DRTS) reported clinical data for Alpha DaRT® combined with pembrolizumab in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma. In a single-center, open-label study, 9 evaluable patients achieved a 100% systemic objective response rate, with 4 complete and 5 partial responses.
According to Alpha Tau, median overall survival reached 18.2 months and median progression-free survival 5.4 months, compared with historical pembrolizumab monotherapy benchmarks of 12.3 and ~3.2 months. No Alpha DaRT-related serious adverse events were seen; only two Grade 1 events occurred. The Simon two-stage design’s success threshold (more than six responders) was surpassed, recruitment was completed at 11 patients, and the company is discussing a larger U.S. study with the FDA. Alpha Tau cautions against direct comparisons with unrelated trials.
Alpha Tau (Nasdaq: DRTS) reported the first successful treatment of an immunocompromised patient with recurrent cutaneous squamous cell carcinoma (cSCC) in its ADMIRE clinical study, evaluating intratumoral Alpha DaRT therapy for this high‑risk group. The procedure was performed at Banner MD Anderson Cancer Center in Gilbert, Arizona, by Dr. Michael Samuels and Dr. Thomas Shellenberger.
ADMIRE targets immunocompromised patients, including organ transplant recipients, those with hematologic malignancies or on chronic immunosuppressive therapy, who face up to a 65–100‑fold higher cSCC incidence and limited treatment options. The trial builds on experience from Alpha Tau’s ReSTART pivotal study for recurrent cSCC, which recently completed enrollment.
Oramed (NASDAQ: ORMP) released a shareholder letter detailing portfolio gains, Scilex loan repayments, and upcoming Russell 2000/3000 index inclusion.
Key points include Alpha Tau's value rising to about $167M, Scilex repayments totaling roughly $118M to date, and total cash and assets of about $270M as of March 31, 2026 (unaudited).
Alpha Tau (Nasdaq: DRTS) reported the first recurrent glioblastoma patient treated with Alpha DaRT outside the US, and first in Israel, at Hadassah University Medical Center. Using a proprietary brain applicator and stereotactic neuro-navigation, sources were implanted via a single minimally invasive burr hole, with the procedure completed safely and without unexpected complications. The case was performed under the ALL broad-access protocol and complements Alpha Tau’s multicenter US REGAIN trial, which recently received FDA clearance to proceed to full enrollment with two additional US academic centers.
Alpha Tau (Nasdaq:DRTS) received FDA clearance to complete enrollment of the final seven patients in its U.S. REGAIN recurrent glioblastoma trial and to add two new U.S. academic cancer centers as sites.
Early interim data from the first three patients showed 100% local disease control, a 67% complete response rate and one grade 3 serious adverse event, which resolved.
The FDA had previously granted Breakthrough Device designation and accepted Alpha Tau into its TPLC TAP Pilot for Alpha DaRT.
Alpha Tau (Nasdaq:DRTS) and Tolmar entered a long‑term U.S. collaboration to develop and commercialize Alpha DaRT for prostate cancer, with an option for bladder cancer.
Tolmar will invest $20M in equity at $11.99 per share, fund $15M for a new U.S. manufacturing facility, and may pay up to $161.5M in development, regulatory and commercial milestones for the initial indication. Alpha Tau will manufacture Alpha DaRT, supplying Tolmar at 60% of net sales, while Tolmar holds exclusive U.S. commercialization rights for prostate cancer for an expected 20‑year term.
Alpha Tau (Nasdaq:DRTS) reported pooled Phase I/II data of Alpha DaRT® in locally advanced and metastatic pancreatic ductal adenocarcinoma, showing median overall survival up to 17.1 months in heavily pretreated patients and 11.2–11.1 months as second-line therapy, versus historical 4–7 and ~9 months. Treatment-associated adverse events occurred in 36% of subjects, Grade ≥3 in 9%, with no treatment-related deaths or chronic toxicity. The data support Alpha DaRT as a one-time, minimally invasive intratumoral therapy and underpin ongoing multicenter trials, including the U.S. IMPACT front-line chemotherapy combination study.
Alpha Tau (NASDAQ: DRTS) reported Q1 2026 results and major clinical milestones for its Alpha DaRT cancer therapy.
Highlights include 100% local disease control in interim U.S. GBM and pancreatic trials, full enrollment of the pivotal U.S. ReSTART cSCC trial, FDA IDE expansion of the IMPACT pancreatic study, and $80.2 million in cash and deposits.
Alpha Tau (NASDAQ:DRTS) announced that CFO Raphi Levy will participate in several May 2026 investor conferences, including events hosted by H.C. Wainwright, Rothschild & Co Redburn, and Lytham Partners.
The schedule features fireside chats, presentations, and 1x1 investor meetings in New York and via virtual webcast.
Alpha Tau (Nasdaq: DRTS) reported interim data from the U.S. REGAIN trial of Alpha DaRT for recurrent glioblastoma. Three patients have been treated so far.
According to Alpha Tau, 100% local disease control was observed, with a 67% complete response rate, favorable safety and one resolved grade 3 SAE.